Klin Farmakol Farm. 2025;39(1):34-43 | DOI: 10.36290/far.2025.015

Drug-drug interactions of DOAC and anticonvulsants

Michal Prokeš, Josef Suchopár
DrugAgency, a. s., Praha

In developed countries, more and more patients are being treated with DOACs, the use of which, unlike until recently preferred warfarin, cannot be easily titrated in common medical practice. It is therefore important, when dosing DOACs, to follow the recommendations issued by the marketing autorisation holders in SmPC and guidelines issued by professional societies of physicians, taking into account the condition of individual patients. Drug interactions of DOACs with specific anticonvulsants may cause a reduction in anticoagulant effect in some patients, and new studies suggest that there may also be an increased risk of bleeding events, for example valproic acid and DOACs. This article provides an overview of the current knowledge on this issue.

Keywords: drug-drug interactions, DOAC, anticonvulsants, thromboembolic complications, bleeding.

Accepted: April 15, 2025; Published: April 29, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prokeš M, Suchopár J. Drug-drug interactions of DOAC and anticonvulsants. Klin Farmakol Farm. 2025;39(1):34-43. doi: 10.36290/far.2025.015.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Yu AYX, Malo S, Swenson LW, et al. Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study. J Am Heart Assoc. 2017;6(11):e007129. Go to original source... Go to PubMed...
    2. Zárubová J, Komárek V. Antiepileptika, in: Suchopár J, et al. Compendium, Léčiva používaná v podmínkách ČR. 2018: str. 231-260.
    3. Galgani A, Palleria C, Iannone F, et al. Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs. Front Neurol. 2018;9:1067. Go to original source... Go to PubMed...
    4. Ambler Z, Bednařík J, Keller O. Doporučený postup pro léčbu neuropatické bolesti. Odborné materiály neuromuskulární sekce České neurologické bolesti. [Internet]. [3.2.2025]. Available from: https://www.neuromuskularni-sekce.cz/index.php?pg=odborne-materialy--doporuceny-postup-pro-lecbu-neuropaticke-bolesti.
    5. Acton EK, Gelfand MA, Hennessy S, et al. Trends in oral anti­coagulant co-prescription with antiepileptic drugs among adults with epilepsy, 2010-2018. Epilepsy Behav. 2020;113: 107550. Go to original source... Go to PubMed...
    6. Táborský M, Kautzner J, Fedorco M, et al. Praktický průvodce Evropské asociace srdečního rytmu pro použîvánî přîmých perorálnîch antikoagulanciî u pacientů s fibrilacî sînî, verze 2021. Překlad dokumentu připravený Českou kardiologickou společnostî. Cor Vasa. 2023;65(Suppl. 1):23-75. Go to original source...
    7. Ranzato F, Roberti R, Deluca C, et al. Pilot study on the probability of drug-drug interactions among direct oral antico­agulants (DOACs) and antiseizure medications (ASMs): a clinical perspective. Neurol Sci. 2024;45(1):277-288. Go to original source... Go to PubMed...
    8. Gronich N, Stein N, Muszkat M. Association Between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study. Clin Pharmacol Ther. 2021;110(6):1526-1536. Go to original source... Go to PubMed...
    9. Ngo LT, Yang SY, Tran QT, et al. Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban. Pharmaceutics. 2020;12(11):1040. Go to original source... Go to PubMed...
    10. Ngo LT, Yun HY, Chae JW. Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug-Drug Interaction between Rivaroxaban and Carbamazepine in Humans. Pharmaceuticals (Basel) 2023;16(5):684. Go to original source... Go to PubMed...
    11. Lutz JD, Kirby BJ, Wang Lu, et al. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. Clin Pharmacol Ther. 2018;104(6):1191-1198. Go to original source... Go to PubMed...
    12. Perlman A, Goldstein R, Cohen LC, et al. Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study. CNS Drugs. 2021;35(3):305-316. Go to original source... Go to PubMed...
    13. Goldstein R, Rabkin N, Buchman N, et al. The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations. CNS Drugs. 2024;38(5):399-408. Go to original source... Go to PubMed...
    14. Laureano M, Crowther M, Eikelboom J, Boonyawat K. Measurement of Dabigatran Drug Levels to Manage Patients Taking Interacting Drugs: A Case Report. Am J Med. 2016;129(10):e247-248. Go to original source... Go to PubMed...
    15. Riselada AJ, Visser MJ, van Roon EN. Pulmonary embolism due to interaction between rivaroxaban and carbamazepine. Ned Tijdschr Geneeskd. 2013;157(52):A6568.
    16. Chadha A, Lopaschuk D, Ackman ML, et al. The problém with predictions: A cautionary tale of empirically adjusting apixaban dosing with carbamazepine. CJC Open. 2022;4: 435-438. Go to original source... Go to PubMed...
    17. Ip BY, Ko H, Wong GL, et al. Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis. CNS Drugs. 2022; 36(12):1313-1324. Go to original source... Go to PubMed...
    18. Josephson CB, Wiebe S, Delgado-Garcia G, et al. Associa­tion of Enzyme-Inducing Antiseizure Drug Use With Long-term Cardiovascular Disease. JAMA Neurol. 2021;78(11): 1367-1374. Go to original source... Go to PubMed...
    19. 29. Chang SH, Chou IJ, Yeh YH, et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA. 2017;318(13):1250-1259. Go to original source... Go to PubMed...
    20. Wang CL, Wu VC, Chang KH, et al. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):147-154. Go to original source... Go to PubMed...
    21. Wiggins BS, Northup A, Johnson D, Senfield J. Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin. Pharmacotherapy. 2016;36(2):e5-7. Go to original source... Go to PubMed...
    22. Hager N, Bolt J, Albers L, et al. Development of Left Atrial Thrombus After Coadministration of Dabigatran Etexilate and Phenytoin. Can J Cardiol. 2017;33(4):554.e13-554.e14. Go to original source... Go to PubMed...
    23. Beccerra AF, Amuchastegui T, Tabares AH. Decreased Rivaroxaban Levels in a Patient with Cerebral Vein Thrombosis Receiving Phenytoin. Case Rep Hematol. 2017: 4760612. Go to original source... Go to PubMed...
    24. Chin PKL, Wright DFB, Zhang M, et al. Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs R D. 2014;14(2):113-123. Go to original source... Go to PubMed...
    25. King PK, Stump TA, Walkama AM, et al. Management of Phenobarbital and Apixaban Interaction in Recurrent Cardioembolic Stroke. Ann Pharmacother. 2018;52(6):605-606. Go to original source... Go to PubMed...
    26. Dagan G, Perlman A, Hochberg-Klein S, et al. Managing Direct Oral Anticoagulants in Patients With Antiepileptic Medication. Can J Cardiol. 2018;34(11):153.4e1-1534.e3. Go to original source... Go to PubMed...
    27. Eyal S, Lamb JG, Smith-Yockman M, et al. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br J Pharmacol. 2006;149(3):250-260. Go to original source... Go to PubMed...
    28. Červený L, Švecová L, Anzenbacherová E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007;35(7): 1032-1041. Go to original source... Go to PubMed...
    29. Olaizola I, Brodde MF, Kehrel BE, Evers S. The Impact of Levetiracetam and Valproate on Platelet Functions-A Double-Blind, Placebo-Controlled Crossover Study. J Clin Med. 2023;12(3):933. Go to original source... Go to PubMed...
    30. Langenbruch L, Meuth SG, Wiendl H, et al. Clinically relevant interaction of rivaroxaban and valproic acid - A case report. Seizure. 2020;80:46-47. Go to original source... Go to PubMed...
    31. SPC ČR: Depakine Chrono® (kyselina valproová), Sanofis.r.o., 7/2024. [Internet]. Available from: https://sukl.gov.cz/verejnost/leciva/.
    32. SPC ČR: Xarelto® (rivaroxaban), Bayer Pharma, 9/2024. [Internet]. Available from: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_cs.pdf.
    33. SPC ČR: Keppra (levetiracetam), UCB Pharma 1/2025. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/keppra-epar-product-information_cs.pdf.
    34. Mavri A, Ilc S. The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam. Sci Rep. 2023;13(1):9257. Go to original source... Go to PubMed...
    35. Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, et al. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol. 2021;21(1):208. Go to original source... Go to PubMed...
    36. Sáez-Torres de Vicente M, Puig PM, Toresano LV, et al. Ischemic stroke due to possible interaction of rivaroxaban with primidone in a patient with atrial fibrillation. Med Clin (Barc) 2021;156(5):255-256. Go to original source... Go to PubMed...
    37. Manis MM, Petersen K, Roberts MZ, Kyle JA. Managing the Drug-Drug Interaction With Apixaban and Primidone: A Case report. Hosp Pharm. 2023;58(4):345-349. Go to original source... Go to PubMed...
    38. Andreasen A, Brosen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia. 2007; 48(3):490-496. Go to original source... Go to PubMed...
    39. Serra W, Calzi ML, Coruzzi P. Left Atrial Appendage Thrombosis During Therapy with Rivaroxaban in Elective Cardioversion for Permanent Atrial Fibrillation. Clin Pract. 2015;5(3):788. Go to original source... Go to PubMed...
    40. Robinson ZS, Arvin JP, Madding KL, et al. Rivaroxaban Failure in a Patient Taking Oxcarbazepine. Ann Pharmacother. 2021;55(10):1302-1303. Go to original source... Go to PubMed...
    41. SPC ČR: Diacomit® (spiripentol), Biocodex, 7/2024 https://www.ema.europa.eu/cs/documents/product-information/diacomit-epar-product-information_cs.pdf.
    42. Kerr BM, Martinez-Lage JM, Viteri C, et al. Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol. Epilepsia. 1991;32(2):267-274. Go to original source... Go to PubMed...
    43. SPC ČR: Fycompa (perampanel), Eisai 5/2023. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/fycompa-epar-product-information_cs.pdf.
    44. SPC ČR: Inovelon® (rufinamid), Eisai GmbH, 12/2023. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/inovelon-epar-product-information_cs.pdf.
    45. Stölberger C, Finsterer J, Schneider B. Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention. Expert Opin Drug Metab Toxicol. 2024;20(5):359-376. Go to original source... Go to PubMed...
    46. Greene SA, Kwak C, Kamin M, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Transl Sci. 2022;15(4):899-911. Go to original source... Go to PubMed...
    47. SPC ČR: Ontozry® (cenobamát), Angelini Pharma, 12/2024. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/ontozry-epar-product-information_cs.pdf.
    48. Bansal S, Zamarripa CA, Spindle TR, et al. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. Clin Pharmacol Ther. 2023; 114(3):693-703. Go to original source... Go to PubMed...
    49. SPC ČR: Epidyolex® (kanabidiol), 9/2024. Jazz Pharmaceuticals Ireland. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/epidyolex-epar-product-information_cs.pdf.
    50. Martin P, Czerwinski M, Limaye PB, et al. In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions. Pharmacol Res Perspect. 2022;10(3):e00959. Go to original source... Go to PubMed...
    51. SPC ČR: Fintepla® (fenfluramin), UCB Pharma 8/2024. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/fintepla-epar-product-information_cs.pdf.
    52. Grymnoprez M, Carnoy L, Capiau A, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2023;9(8):722-730. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.